The class of TEF-3 inhibitors comprises a set of chemicals meticulously selected for their ability to modulate the activity of the transcription factor TEF-3 through targeted interference with specific signaling pathways. These inhibitors operate primarily through the Rho-associated coiled-coil kinase (ROCK) pathway, showcasing a nuanced understanding of the intricate molecular mechanisms governing TEF-3. Chemicals such as CAY10576, Y-27632, HA-1077 (Fasudil), GSK429286A, RKI-1447, SR3677, FSD-C10, H-1152, AT13148, Y-39983, and Ripasudil (K-115) act as selective ROCK inhibitors, disrupting the downstream signaling cascade of ROCK and consequently inhibiting TEF-3. This elucidates the pivotal role of ROCK-mediated signaling in the regulation of TEF-3 activity, presenting a targeted approach for interventions in cellular processes governed by TEF-3.
Additionally, the class includes H-89, which operates as a protein kinase A (PKA) inhibitor, providing a dual strategy for TEF-3 inhibition. By interfering with the signaling pathways influenced by PKA, H-89 contributes to the comprehensive understanding of TEF-3 regulation. The collective action of these inhibitors emphasizes the specificity of the chosen chemicals in influencing distinct molecular pathways, showcasing the abilities of ROCK and PKA pathways as key regulators of TEF-3 activity. This chemical class provides a valuable resource for researchers investigating the intricate network of signaling cascades involved in TEF-3 modulation, laying the groundwork for further exploration into the fundamental molecular mechanisms underlying TEF-3 function and its implications in cellular processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 inhibits TEF-3 by targeting the Rho-associated coiled-coil kinase (ROCK) pathway. As a potent and selective ROCK inhibitor, Y-27632 disrupts the signaling cascade downstream of ROCK, resulting in the inhibition of TEF-3. This emphasizes the significance of ROCK-mediated signaling in regulating TEF-3 activity, providing a potential avenue for intervention through the use of Y-27632. | ||||||
GSK 429286 | 864082-47-3 | sc-361200 sc-361200B sc-361200A | 1 mg 5 mg 10 mg | $40.00 $125.00 $235.00 | ||
GSK429286A inhibits TEF-3 by targeting the Rho-associated coiled-coil kinase (ROCK) pathway. As a selective ROCK inhibitor, GSK429286A disrupts the signaling cascade downstream of ROCK, ultimately leading to the inhibition of TEF-3. This emphasizes the role of ROCK-mediated signaling in modulating TEF-3 activity and positions GSK429286A as a potential inhibitor through its specific action on the ROCK pathway. | ||||||
RKI-1447 | 1342278-01-6 | sc-472590 | 1 mg | $330.00 | ||
RKI-1447 inhibits TEF-3 by specifically targeting the Rho-associated coiled-coil kinase (ROCK) pathway. As a selective ROCK inhibitor, RKI-1447 disrupts the downstream signaling cascade, resulting in the inhibition of TEF-3. This highlights the significance of the ROCK pathway in regulating TEF-3 activity and positions RKI-1447 as a potential inhibitor through its specific action on ROCK-mediated signaling. | ||||||
H-1152 dihydrochloride | 451462-58-1 | sc-203592 sc-203592A | 1 mg 5 mg | $104.00 $364.00 | 7 | |
H-1152 Dihydrochloride inhibits TEF-3 by acting as a Rho-associated coiled-coil kinase (ROCK) inhibitor. By disrupting ROCK-mediated signaling, H-1152 modulates the downstream pathways that influence TEF-3 activity. This underscores the importance of the ROCK pathway in regulating TEF-3 and positions H-1152 as a potential inhibitor through its specific action on ROCK. | ||||||